ABCC3
ATP-binding cassette sub-family C member 3
Also known as: cMOAT2, EST90757, MLP2, MOAT-D, MRP3, MRP3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O15438
- Gene
- ABCC3
- Ensembl
- ENSG00000108846
- Chromosome
- 17
- Canonical length
- 1527 aa
- Protein class
- Cancer-related genes, Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters
- Subcellular location
- Plasma membrane,Basal body
OverviewNCBI Gene
The protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MRP subfamily which is involved in multi-drug resistance. The specific function of this protein has not yet been determined; however, this protein may play a role in the transport of biliary and intestinal excretion of organic anions. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
1527 residues, UniProt reviewed canonical sequence.
>O15438|ABCC3
1 MDALCGSGEL GSKFWDSNLS VHTENPDLTP CFQNSLLAWV PCIYLWVALP CYLLYLRHHC
61 RGYIILSHLS KLKMVLGVLL WCVSWADLFY SFHGLVHGRA PAPVFFVTPL VVGVTMLLAT
121 LLIQYERLQG VQSSGVLIIF WFLCVVCAIV PFRSKILLAK AEGEISDPFR FTTFYIHFAL
181 VLSALILACF REKPPFFSAK NVDPNPYPET SAGFLSRLFF WWFTKMAIYG YRHPLEEKDL
241 WSLKEEDRSQ MVVQQLLEAW RKQEKQTARH KASAAPGKNA SGEDEVLLGA RPRPRKPSFL
301 KALLATFGSS FLISACFKLI QDLLSFINPQ LLSILIRFIS NPMAPSWWGF LVAGLMFLCS
361 MMQSLILQHY YHYIFVTGVK FRTGIMGVIY RKALVITNSV KRASTVGEIV NLMSVDAQRF
421 MDLAPFLNLL WSAPLQIILA IYFLWQNLGP SVLAGVAFMV LLIPLNGAVA VKMRAFQVKQ
481 MKLKDSRIKL MSEILNGIKV LKLYAWEPSF LKQVEGIRQG ELQLLRTAAY LHTTTTFTWM
541 CSPFLVTLIT LWVYVYVDPN NVLDAEKAFV SVSLFNILRL PLNMLPQLIS NLTQASVSLK
601 RIQQFLSQEE LDPQSVERKT ISPGYAITIH SGTFTWAQDL PPTLHSLDIQ VPKGALVAVV
661 GPVGCGKSSL VSALLGEMEK LEGKVHMKGS VAYVPQQAWI QNCTLQENVL FGKALNPKRY
721 QQTLEACALL ADLEMLPGGD QTEIGEKGIN LSGGQRQRVS LARAVYSDAD IFLLDDPLSA
781 VDSHVAKHIF DHVIGPEGVL AGKTRVLVTH GISFLPQTDF IIVLADGQVS EMGPYPALLQ
841 RNGSFANFLC NYAPDEDQGH LEDSWTALEG AEDKEALLIE DTLSNHTDLT DNDPVTYVVQ
901 KQFMRQLSAL SSDGEGQGRP VPRRHLGPSE KVQVTEAKAD GALTQEEKAA IGTVELSVFW
961 DYAKAVGLCT TLAICLLYVG QSAAAIGANV WLSAWTNDAM ADSRQNNTSL RLGVYAALGI
1021 LQGFLVMLAA MAMAAGGIQA ARVLHQALLH NKIRSPQSFF DTTPSGRILN CFSKDIYVVD
1081 EVLAPVILML LNSFFNAIST LVVIMASTPL FTVVILPLAV LYTLVQRFYA ATSRQLKRLE
1141 SVSRSPIYSH FSETVTGASV IRAYNRSRDF EIISDTKVDA NQRSCYPYII SNRWLSIGVE
1201 FVGNCVVLFA ALFAVIGRSS LNPGLVGLSV SYSLQVTFAL NWMIRMMSDL ESNIVAVERV
1261 KEYSKTETEA PWVVEGSRPP EGWPPRGEVE FRNYSVRYRP GLDLVLRDLS LHVHGGEKVG
1321 IVGRTGAGKS SMTLCLFRIL EAAKGEIRID GLNVADIGLH DLRSQLTIIP QDPILFSGTL
1381 RMNLDPFGSY SEEDIWWALE LSHLHTFVSS QPAGLDFQCS EGGENLSVGQ RQLVCLARAL
1441 LRKSRILVLD EATAAIDLET DNLIQATIRT QFDTCTVLTI AHRLNTIMDY TRVLVLDKGV
1501 VAEFDSPANL IAARGIFYGM ARDAGLALocalizationUniProt · AlphaFold · HPA
Whether an antibody against ABCC3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 17
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 58 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 58 nTPM
- liver: 49 nTPM
- pancreas: 23 nTPM
- colon: 19 nTPM
- stomach: 17 nTPM
- small intestine: 12 nTPM
Single-cell type
- adrenal cortex cells: 816 nCPM
- platelets: 721 nCPM
- foveolar cells: 490 nCPM
- hepatocytes: 420 nCPM
- cholangiocytes: 416 nCPM
- colonocytes: 358 nCPM
Immune cell
- non-classical monocyte: 6.4 nTPM
- total PBMC: 5.4 nTPM
- intermediate monocyte: 5.1 nTPM
- classical monocyte: 2.3 nTPM
- myeloid DC: 1.3 nTPM
- neutrophil: 1 nTPM
Brain region
- medulla oblongata: 14 nTPM
- thalamus: 7.7 nTPM
- white matter: 6.6 nTPM
- spinal cord: 5.5 nTPM
- pons: 4.6 nTPM
- cerebral cortex: 4.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ABCC3.
Disease | ImmuneIEDB
Conditions an epitope on ABCC3 was assayed in.
- castration-resistant prostate carcinoma B and T cell
- biliary tract cancer B and T cell
- carcinoma B and T cell
- triple-receptor negative breast cancer B and T cell
- Her2-receptor negative breast cancer B and T cell
- Her2-receptor positive breast cancer B and T cell
- colorectal cancer B and T cell
- synovial sarcoma B and T cell
- chondrosarcoma B and T cell
- prostate cancer B and T cell
- prostatic urethral cancer B and T cell
- cancer B cell
- pancreatic carcinoma B cell
- lung small cell carcinoma B cell
- adult hepatocellular carcinoma B cell
- esophageal cancer B and T cell
- hematologic cancer B cell
- hepatocellular carcinoma B cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against ABCC3 are reported. Each links to that disease's full target list.
Showing 0 of 1 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for ABCC3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma.
2013 · Clin Transl Oncol · RCR 0.6 · 18 citations - Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
2012 · J Cancer Res Clin Oncol · RCR 0.5 · 17 citations - A study of natural IgG antibodies against ATP-binding cassette subfamily C member 3 in oral squamous cell carcinoma.
2019 · J Cancer Res Ther · RCR 0.3 · 6 citations
Reference: B cellIEDB
15 publications
- Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
2014 · Cancer Immunol Res · RCR 1 · 43 citations - Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
2013 · Cancer Sci · RCR 1 · 38 citations - A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.
2017 · Cancer Sci · RCR 1 · 35 citations - Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
2014 · Breast Cancer Res · RCR 0.9 · 36 citations - Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
2012 · Prostate · RCR 0.8 · 36 citations
Show 10 more
- A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
2011 · Prostate · RCR 0.7 · 31 citations - Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
2015 · Cancer Immunol Immunother · RCR 0.6 · 22 citations - Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases.
2013 · Dev Comp Immunol · RCR 0.4 · 15 citations - Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
2018 · Cancer Sci · RCR 0.4 · 12 citations - Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.
2017 · Clin Lung Cancer · RCR 0.4 · 14 citations - Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
2020 · Int J Oncol · RCR 0.2 · 5 citations - Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
2017 · Cancer Sci · RCR 0.2 · 6 citations - Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
2016 · Cancer Immunol Immunother · RCR 0.1 · 3 citations - Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer.
2016 · Evid Based Complement Alternat Med · RCR 0 · 1 citations - Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer.
2021 · Mol Clin Oncol
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.9
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.63
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- bile acid and bile salt transport
- leukotriene transport
- transmembrane transport
- transport across blood-brain barrier
- xenobiotic metabolic process
- xenobiotic transmembrane transport
- xenobiotic transport
Molecular functions
- ABC-type bile acid transporter activity
- ABC-type glutathione S-conjugate transporter activity
- ABC-type transporter activity
- ABC-type xenobiotic transporter activity
- ATP binding
- ATP hydrolysis activity
- ATPase-coupled inorganic anion transmembrane transporter activity
- ATPase-coupled transmembrane transporter activity
- xenobiotic transmembrane transporter activity
- glucuronoside transmembrane transporter activity
- icosanoid transmembrane transporter activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- ABC transporter-like, ATP-binding domain
- AAA+ ATPase domain
- Multi drug resistance-associated protein
- ABC transporter type 1, transmembrane domain
- ABC transporter-like, conserved site
- P-loop containing nucleoside triphosphate hydrolase
- ABC transporter type 1, transmembrane domain superfamily
- ATP-binding cassette transporter C-like
- ABC transporter, TMD0 domain
- ABC transporter
- ABC transporter transmembrane region
- ABC transporter TMD0 domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ABCC3 as an antibody target. Whether an autoantibody or antibody against ABCC3 could matter depends on whether native ABCC3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ABCC3 is annotated at the cell surface, where native ABCC3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ABCC3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...